Assess whether RWE can replace or only supplement an RCT (749883)

Situation

After an FAERS cluster in a demographic the trials under-enrolled, phase-3 protocol with endpoint-sensitivity issues is what pediatric-plan strategist can touch in a 505(b)(2) program relying on literature plus a bridging study. Pharma & Life Sciences will live with RWE can replace versus Only supplement an RCT on this Clinical and Evidence Strategy file.

Decision

Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose RWE can replace / Only supplement an RCT using phase-3 protocol with endpoint-sensitivity issues after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• Authorize RWE can replace now; phase-3 protocol with endpoint-sensitivity issues already has the discriminator after an FAERS cluster in a demographic the trials under-enrolled.
• Keep Only supplement an RCT in force until phase-3 protocol with endpoint-sensitivity issues is completed after an FAERS cluster in a demographic the trials under-enrolled for pediatric-plan strategist.
• Treat phase-3 protocol with endpoint-sensitivity issues as RWE can replace because both readings appear after an FAERS cluster in a demographic the trials under-enrolled.
• Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the page RWE can replace or turns on in phase-3 protocol with endpoint-sensitivity issues.

Analysis required

• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after an FAERS cluster in a demographic the trials under-enrolled.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read phase-3 protocol with endpoint-sensitivity issues against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move RWE can replace or for pediatric-plan strategist.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (phase-3 protocol with endpoint-sensitivity issues after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study.